Cartesian Therapeutics, Inc.
RNAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $463,959 | $101,648 | $136,314 | $310,593 |
| - Cash | $212,610 | $76,911 | $106,438 | $114,057 |
| + Debt | $13,984 | $10,955 | $37,925 | $35,281 |
| Enterprise Value | $265,333 | $35,692 | $67,801 | $231,817 |
| Revenue | $38,913 | $26,004 | $110,777 | $85,077 |
| % Growth | 49.6% | -76.5% | 30.2% | – |
| Gross Profit | $38,913 | $26,004 | $108,740 | $85,077 |
| % Margin | 100% | 100% | 98.2% | 100% |
| EBITDA | -$75,986 | -$235,034 | $39,838 | -$5,158 |
| % Margin | -195.3% | -903.8% | 36% | -6.1% |
| Net Income | -$77,424 | -$219,710 | $35,379 | -$25,687 |
| % Margin | -199% | -844.9% | 31.9% | -30.2% |
| EPS Diluted | -3.29 | -49.76 | 3 | -6.6 |
| % Growth | 93.4% | -1,758.7% | 145.5% | – |
| Operating Cash Flow | -$23,674 | -$51,161 | -$31,631 | -$60,382 |
| Capital Expenditures | -$9,093 | -$206 | -$1,201 | -$1,085 |
| Free Cash Flow | -$32,767 | -$51,367 | -$32,832 | -$61,467 |